WallStreetZenWallStreetZen

NASDAQ: BLRX
Biolinerx Ltd Stock

$1.60+0.00 (+0%)
Updated Jun 6, 2023
BLRX Price
$1.60
Fair Value Price
$1.87
Market Cap
$98.94M
52 Week Low
$0.55
52 Week High
$1.98
P/E
-53.33x
P/B
2.53x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$32.18M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.76
Operating Cash Flow
-$29M
Beta
0.62
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

BLRX Overview

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

Zen Score

Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BLRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

BLRX ($1.60) is undervalued by 14.23% relative to our estimate of its Fair Value price of $1.87 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
BLRX ($1.60) is not significantly undervalued (14.23%) relative to our estimate of its Fair Value price of $1.87 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
BLRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BLRX due diligence checks available for Premium users.

Be the first to know about important BLRX news, forecast changes, insider trades & much more!

BLRX News

Valuation

BLRX fair value

Fair Value of BLRX stock based on Discounted Cash Flow (DCF)
Price
$1.60
Fair Value
$1.87
Undervalued by
14.23%
BLRX ($1.60) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BLRX ($1.60) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BLRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

BLRX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-53.33x
Industry
11.67x
Market
53.54x

BLRX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
2.53x
Industry
5.27x
BLRX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

BLRX's financial health

Profit margin

Revenue
$0.0
Net Income
-$12.2M
Profit Margin
0%
BLRX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$68.6M
Liabilities
$29.5M
Debt to equity
0.76
BLRX's short-term assets ($44.33M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BLRX's short-term assets ($44.33M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BLRX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
BLRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$8.0M
Investing
$6.6M
Financing
-$49.0k
BLRX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

BLRX vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
BLRX$98.94M0.00%-53.33x2.53x
KRON$97.97M0.00%-0.78x0.43x
ETON$97.94M+0.52%-16.00x8.71x
GNTA$100.74M-5.57%-10.72x2.94x
ONCY$101.11M-3.66%-5.11x5.34x

Biolinerx Stock FAQ

What is Biolinerx's quote symbol?

(NASDAQ: BLRX) Biolinerx trades on the NASDAQ under the ticker symbol BLRX. Biolinerx stock quotes can also be displayed as NASDAQ: BLRX.

If you're new to stock investing, here's how to buy Biolinerx stock.

What is the 52 week high and low for Biolinerx (NASDAQ: BLRX)?

(NASDAQ: BLRX) Biolinerx's 52-week high was $1.98, and its 52-week low was $0.55. It is currently -19.15% from its 52-week high and 193.58% from its 52-week low.

How much is Biolinerx stock worth today?

(NASDAQ: BLRX) Biolinerx currently has 922,958,942 outstanding shares. With Biolinerx stock trading at $1.60 per share, the total value of Biolinerx stock (market capitalization) is $98.94M.

Biolinerx stock was originally listed at a price of $75.45 in Jul 27, 2011. If you had invested in Biolinerx stock at $75.45, your return over the last 11 years would have been -97.88%, for an annualized return of -29.55% (not including any dividends or dividend reinvestments).

How much is Biolinerx's stock price per share?

(NASDAQ: BLRX) Biolinerx stock price per share is $1.60 today (as of Jun 6, 2023).

What is Biolinerx's Market Cap?

(NASDAQ: BLRX) Biolinerx's market cap is $98.94M, as of Jun 7, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Biolinerx's market cap is calculated by multiplying BLRX's current stock price of $1.60 by BLRX's total outstanding shares of 922,958,942.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.